SmallCapReview.com has been a leading site for information on small cap stocks, penny stocks and microcaps since 1999.
Teva Pharmaceutical Industries (Nasdaq: TEVA) $49.27. Today announced along with Active Biotech initial results from the two-year Phase III ALLEGRO study, which demonstrated that relapsing-remitting multiple sclerosis (MS) patients treated with 0.6 mg daily oral laquinimod experienced a statistically significant reduction in annualized relapse rate compared to placebo. Additional clinical endpoints, including significant reduction in disability progression, as measured by Expanded Disability Severity Scale (EDSS), were also achieved.
Laquinimod was safe and well-tolerated. The overall frequencies of adverse events were comparable to those observed in the placebo group. No deaths were reported in laquinimod-treated patients. Overall incidence of infections was similar between the two arms of the trial.
"This pivotal study met its primary endpoint while maintaining a very good safety profile," says Principal Investigator, Professor Giancarlo Comi, Director of the Department of Neurology and Institute of Experimental Neurology at the University Vite Salute, San Raffaele, Italy. "Laquinimod demonstrated a significant reduction in the progression of disability which may be explained by its unique mechanism of action that includes neuroprotective properties. Laquinimod may therefore be a promising therapeutic option for the MS community."
What They Do: Teva Pharmaceutical Industries is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients.
lululemon athletica (Nasdaq: LULU) $56.07. Today announced financial results for the third quarter ended October 31, 2010. For the thirteen weeks ended October 31, 2010: Net revenue for the quarter increased 56% to $175.8 million from $112.9 million in the third quarter of fiscal 2009. Net revenue from corporate-owned stores was $143.2 million for the quarter, an increase of 46% from $98.1 million in the third quarter of fiscal 2009, and comparable-store sales increased by 29% on a constant-dollar basis.
Gross profit for the quarter increased by 72% to $96.8 million, and as a percentage of net revenue gross profit increased to 55% for the quarter from 50% in the third quarter of fiscal 2009. Income from operations for the quarter increased by 103% to $42.4 million, and as a percentage of net revenue was 24% compared to 19% of net revenue in the third quarter of fiscal 2009. Diluted earnings per share for the quarter was $0.36 on net income of $25.7 million, compared to diluted earnings per share of $0.20 on net income of $14.1 million in the third quarter of fiscal 2009.What They Do: lululemon athletica is a yoga-inspired athletic apparel company that creates components for people to live longer, healthier and more fun lives.
ASML Holding (Nasdaq: ASML) $35.17. Today announced it sees stronger than expected demand for lithography equipment, coming from most semiconductor market segments; while DRAM lithography demand is weakening less than originally planned, NAND Flash memory investments for the high volume ramp of new technologies and Foundry/Logic commitments for new strategic fab projects are driving brisk lithography demand for 2011.
As a result of this demand, ASML is increasing the expectation for fourth quarter system order intake: we now expect Q4 bookings to be above EUR 2 billion. Our previous forecast, issued at the time of publication of our third quarter earnings on October 13, 2010, was for Q4 bookings to exceed the Q3 level of EUR 1.3 billion worth of systems.
What They Do: ASML is the world's leading provider of lithography systems for the semiconductor industry, manufacturing complex machines that are critical to the production of integrated circuits or chips.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit www.SmallCapReview.com.
